首页> 外文期刊>AACN advanced critical care >Medication Therapy for Early-Onset Neonatal Sepsis
【24h】

Medication Therapy for Early-Onset Neonatal Sepsis

机译:早期新生儿脓毒症的药物治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Suspected sepsis is a common cause of morbidity and mortality in neonates. In a population-based surveillance study from 2005 to 2008, researchers estimated that 3300 cases of early-onset sepsis (EOS) occur in the United States each year, with 390 of these cases resulting in death. The risk is highest in preterm neonates, which account for 1570 of the 3300 cases and 360 deaths. Despite its prevalence, though, identifying patients with sepsis, determining causative organisms, and establishing a length of treatment remain a challenge for health care practitioners. Sepsis in neonates can be classified as either early onset or late onset. No single definition for EOS exists, but most often it is described as infection of the bloodstream or meninges that occurs within the first 6 days of life. The most commonly implicated organisms are group B streptococci (GBS) and Escherichia coli, which are most often acquired via vertical transmission from the mother during the intrapartum period.
机译:None

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号